The Trump administration is proposing a voluntary program by which pharmaceutical corporations can provide rebates for a small variety of therapies to hospitals that take part in a federal drug low cost program, an effort to type out an issue that has roiled the well being care business.
At situation is the 340B low cost program, which was created to assist hospitals and clinics look after low-income and rural sufferers. Drug corporations that need to participate in Medicare or Medicaid should provide their medicines at a reduction — usually, 25% to 50%, however typically increased — to taking part hospitals and clinics. Proper now, drug corporations usually present the reductions on the time of buy.
Since its inception greater than three a long time in the past, the program has ballooned — there are actually about 55,000 taking part entities — and has usually factored into the conflict within the U.S. over drug costs. Prescription medicines bought underneath this system amounted to $66.3 billion in 2023, a 23.4% improve from the earlier yr, in keeping with federal authorities information.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
